PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-359

This is exactly what i was talking about in my earlier post yesterday. Bringing MT as CEO and Manging director will add credibility, energy and confidence to the Board and Investors. The new addition of Dr Wallis, a neuroscientist who will get adequate support from world class technical advisory board cements this new management will make a paradigm shift to PAA

I believe SP appreciation starts from here and next week result on updated ALSFRS-R and Survival Analysis to be generated by Berry Consultants will prove, we're in right track to treat MND.